Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase.

about

Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase.

Item

http://www.wikidata.org/entity/Q55509033

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@en

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@nl

type

Item

label

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@en

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@nl

prefLabel

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@en

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@nl

P1476

Antibody-assisted target ident ...... ting ribonucleotide reductase.

@en

P2093

Cheng-Han Yu

http://www.w3.org/2001/XMLSchema#string

Chi-Chi Chou

http://www.w3.org/2001/XMLSchema#string

Geen-Dong Chang

http://www.w3.org/2001/XMLSchema#string

Hsin-Fang Tu

http://www.w3.org/2001/XMLSchema#string

Kay-Hooi Khoo

http://www.w3.org/2001/XMLSchema#string

Ming-Shyue Lee

http://www.w3.org/2001/XMLSchema#string

Wei-Chieh Huang

http://www.w3.org/2001/XMLSchema#string

Ya-Yeh Ho

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

EGF receptor trafficking: consequences for signaling and cancer

Developing irreversible inhibitors of the protein kinase cysteinome

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

P304

21512-21529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25177

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29765556

http://www.w3.org/2001/XMLSchema#string

P932

5940374

http://www.w3.org/2001/XMLSchema#string